Funded by the Defense Threat Reduction Agency, UT researchers are discovering and developing antimicrobial peptides to combat antimicrobial resistance biothreat pathogens. And with DARPA, we are developing nasal-based microbe neuromodulator delivery for in situ production of therapeutic peptides.
